Resistance to abiraterone in castration-resistant prostate cancer: A review of the literature

Anticancer Research

Volumn 34, Issue 11, 2014, Pages 6265-6269

  Giacinti, Silvana ^a   Bassanelli, Maria ^a   Aschelter, Anna Maria ^a   Milano, Annalisa ^a   Roberto, Michela ^a   Marchetti, Paolo ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Abiraterone; Castration resistant prostate cancer; Prostate cancer; Resistance; Resistance to abiraterone; Review

Indexed keywords

ABIRATERONE; ANDROGEN RECEPTOR; CYTOCHROME P450 17; DEXAMETHASONE; DIHYDROTACHYSTEROL; MAMMALIAN TARGET OF RAPAMYCIN; MICRORNA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN TYROSINE KINASE A; ANDROSTANE DERIVATIVE;

ALTERNATIVE RNA SPLICING; APOPTOSIS; CANCER STEM CELL; CASTRATION RESISTANT PROSTATE CANCER; CELL METABOLISM; CELL PROLIFERATION; CELL SURVIVAL; EPITHELIAL MESENCHYMAL TRANSITION; GLUCURONIDATION; HUMAN; NONHUMAN; PROTEIN SYNTHESIS; REVIEW; SIGNAL TRANSDUCTION; UPREGULATION; ANIMAL; DRUG RESISTANCE; LITERATURE; MALE; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT;

ANDROSTENOLS; ANIMALS; DRUG RESISTANCE, NEOPLASM; HUMANS; MALE; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; REVIEW LITERATURE AS TOPIC;

EID: 84916206178     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. Titus MA, Schell MJ, Lih FB, Tomer KB and Mohler JL: Testosterone and di-hydrotestosterone tissue levels in recurrent prostate cancer. Clin Cancer Res 11: 4653-4467, 2005.
2. Montgomery RB, Mostaghel EA, Vessella R, Hess DL, Kalhorn TF, Higano CS, True LD and Nelson PS: Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res 68(11): 4447-4454, 2008.
3. Labrie F, Bélanger A, Simard J, Van Luu-The and Labrie C: DHEA and peripheral androgen and estrogen formation: intracinology. Ann NY Acad Sci 774 : 16-28, 1995.
4. Locke JA, Guns ES, Lubik AA, Adomat HH, Hendy SC, Wood CA, Ettinger SL, Gleave ME and Nelson CC: Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res 68( 15): 6407-6415, 2008.
5. Chang KH, Li R, Papari-Zareei M, Watumull L, Zhao YD, Auchus RJ and Sharifi N: Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer. Proc Natl Acad Sci USA 108 : 13728-13733, 2011.
6. Li R, Evaul K, Sharma KK, Chang K-H, Yoshimoto J, Liu J, Auchus RJ and Sharifi N: Abiraterone inhibits 3β- hydroxysteroid dehydrogenase: a rationale for increasing drug exposure in castration-resistant prostate cancer. Clin Cancer Res 18: 3571-3579, 2012.
7. Richards J, Lim AC, Hay CW, Taylor AE, Wingate A, Nowakowska K, Pezaro C, Carreira S, Goodall J, Arlt W, McEwan IJ, De Bono JS and Attard G: Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100. Cancer Res 72: 2176-82, 2012.
8. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB Jr, Saad F, Staffurth JN, Mainwaring P, Harland S, Flaig TW, Hutson TE, Cheng T, Patterson H, Hainsworth JD, Ryan CJ, Sternberg CN, Ellard SL, Fléchon A, Saleh M, Scholz M, Efstathiou E, Zivi A, Bianchini D, Loriot Y, Chieffo N, Kheoh T, Haqq CM and Scher HI; COU-AA-301 Investigators: Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364 : 1995-2000, 2011.
9. Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S, Carles J, Mulders PF, Basch E, Small EJ, Saad F, Schrijvers D, Van Poppel H, Mukherjee SD, Suttmann H, Gerritsen WR, Flaig TW, George DJ, Yu EY, Efstathiou E, Pantuck A, Winquist E, Higano CS, Taplin ME, Park Y, Kheoh T, Griffin T, Scher HI and Rathkopf DE; COU-AA-302 Investigators: Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 368(2): 138-148, 2013.
10. Mostaghel EA, Marck BT, Plymate SR, Vessella RL, Balk S, Matsumoto AM, Nelson PS and Montgomery RB: Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants. Clin Cancer Res 17(18): 5913-5925, 2011.
11. Cai C, Chen S, Ng P, Bubley GJ, Nelson PS, Mostaghel EA, Marck B, Matsumoto AM, Simon NI, Wang H, Chen S and Balk SP: Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors. Cancer Res 71:6503-6513, 2011.
12. Efstathiou E, Titus M, Tsavachidou D, Tzelepi V, Wen S, Hoang A, Molina A, Chieffo N, Smith LA, Karlou M, Troncoso P and Logothetis CJ: Effects of abiraterone acetate on androgen signaling in castrate-resistant prostate cancer in bone. J Clin Oncol 30( 6): 637-643, 2012.
13. Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Chen Y, Roeser JC, Fedor HL, Lotan TL, Zheng Q, De Marzo AM, Isaacs JT, Isaacs WB, Nadal R, Paller CJ, Denmeade SR, Carducci MA, Eisenberger MA and Luo J: Androgen receptor splice variant, AR-V7, and resistance to enzalutamide and abiraterone in men with metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol 32: 5s, 2014.
14. Grigoryev DN, Long BJ, Njar VC and Brodie AH: Pregnenolone stimulates LNCaP prostate cancer cell growyh via the mutated androgen receptor. J Steroid Biochem Mol Biol 75: 1-10, 2000.
15. Attard G, Reid AH, Yap TA, Raynaud F, Dowsett M, Settatree S, Barrett M, Parker C, Martins V, Folkerd E, Clark J, Cooper CS, Kaye SB, Dearnaley D, Lee G and de Bono JS: Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer (CRPC) commonly remains hormone-driven. J Clin Oncol 26 : 4563-4571, 2008.
16. Zhao XY, Malloy PJ, Krishnan AV, Swami S, Navone NM, Peehl DM and Feldman D: Glucocorticoids can promote androgenindependent growth of prostate cancer cells through a mutated androgen receptor. Nat Med 6(6): 703-706, 2000.
17. Attard G, Reid AH, Auchus RJ, Hughes BA, Cassidy AM, Thompson E, Oommen NB, Folkerd E, Dowsett M, Arlt W and de Bono JS: Clinical and biochemical consequences of CYP17A1 inhibition with abiraterone given with and without exogenous glucocorticoids in castrate men with advanced prostate cancer. J Clin Endocrinol Metab 97(2): 507-516, 2012.
18. Attard G, Reid AH, A'Hern R, Parker C, Oommen NB, Folkerd E, Messiou C, Molife LR, Maier G, Thompson E, Olmos D, Sinha R, Lee G, Dowsett M, Kaye SB, Dearnaley D, Kheoh T, Molina A and de Bono JS: Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol 27(23) : 3742-3748, 2009.
19. Culig Z, Hobisch A, Cronauer MV, Cato AC, Hittmair A, Radmayr C, Eberle J, Bartsch G and Klocker H: Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone. Mol Endocrinol 7(12) : 1541-1550, 1993.
20. Mohler JL, Titus MA, Bai S, Kennerley BJ, Lih FB, Tomer KB and Wilson EM: Activation of the androgen receptor by intratumoral bioconversion of androstenediol to dihydrotestosterone in prostate cancer. Cancer Res 71 : 1486-1496, 2011.
21. Belanger A, Pelletier G, Labrie F, Barbier O and Chouinard S: Inactivation of androgens by UDP-glucuronosyltransferase enzymes in humans. Tends Endocrinol Metab 14: 473-479, 2003.
22. Li F and Mahato RI: MicroRNAs and drug resistance in prostate cancers. Mol Pharm 29, 2014.
23. Waltering KK, Porkka KP, Jalava SE, Urbanucci A, Kohonen PJ, Latonen LM, Kallioniemi OP, Jenster G and Visakorpi T: Androgen regulation of microRNAs in prostate cancer. Prostate 71: 604-614, 2011.
24. Östling P, Leivonen S-K, Aakula A, Kohonen P, Mäkelä R, Hagman Z, Edsjö A, Kangaspeska S, Edgren H, Nicorici D, Bjartell A, Ceder Y, Perälä M and Kallioniemi O: Systematic analysis of microRNAs targeting the androgen receptor in prostate cancer cells. Cancer Res 71: 1956-1967, 2011.
25. Ribas J, Ni X, Haffner M, Wentzel EA, Salmasi AH, Chowdhury WH, Kudrolli TA, Yegnasubramanian S, Luo J, Rodriguez R, Mendell JT and Lupold SE: MiR-21: an androgen receptorregulated microRNA that promotes hormone-dependent and hormone-independent prostate cancer growth. Cancer Res 69:7165-7169, 2009.
26. Xu B, Wang N, Wang X, Tong N, Shao N, Tao J, Li P, Niu X, Feng N, Zhang L, Hua L, Wang Z and Chen M: MiR-146a suppresses tumor growth and progression by targeting EGFR pathway and in a p-ERK-dependent manner in castrationresistant prostate cancer. Prostate 72(11): 1171-1178, 2012.
27. Nadiminty N, Tummala R, Lou W, Zhu Y, Shi XB, Zou JX, Chen H, Zhang J, Chen X, Luo J, deVere White RW, Kung HJ, Evans CP and Gao AC: MicroRNA let-7c is down-regulated in prostate cancer and suppresses prostate cancer growth. PLoS One 7(3): e32832, 2012.
28. Shi XB, Xue L, Ma AH, Tepper CG, Gandour-Edwards R, Kung HJ and deVere White RW: Tumor-suppressive miR-124 targets androgen receptor and inhibits proliferation of prostate cancer cells. Oncogene 32(35): 4130-4138, 2013.
29. Kashat M, Azzouz L, Sarkar SH, Kong D, Li Y and Sarkar FH: Inactivation of AR and NOTCH-1 signaling by miR-34a attenuates prostate cancer aggressiveness. Am J Transl Res 4(4):432-442, 2012.
30. Fujita Y, Kojima K, Ohhashi R, Hamada N, Nozawa Y, Kitamoto A, Sato A, Kondo S, Kojima T, Deguchi T and Ito M: miR-148a attenuates paclitaxel resistance of hormone-refractory, drug resistant prostate cancer PC3 cells by regulating MSK1 expression. J Biol Chem 285(25): 19076-19084, 2010.
31. Lin PC, Lin PC, Chiu YL, Banerjee S, Park K, Mosquera JM, Giannopoulou E, Alves P, Tewari AK, Gerstein MB, Beltran H, Melnick AM, Elemento O, Demichelis F and Rubin MA: Epigenetic repression of miR-31 disrupts androgen receptor homeostasis and contributes to prostate cancer progression. Cancer Res 73(3): 1232-1244, 2013.
32. He M, Liu Y, Deng X, Qi S, Sun X, Liu G and Zhao M: Downregulation of miR-200b-3p by low p73 contributes to the androgen-independence of prostate cancer cells. Prostate 73(10):1048-1056, 2013.
33. Qu F, Cui X, Hong Y, Wang J, Li Y, Chen L, Liu Y, Gao Y, Xu D and Wang Q: MicroRNA-185 suppresses proliferation, invasion, migration, and tumorigenicity of human prostate cancer cells through targeting androgen receptor. Mol Cell Biochem 377(1-2): 121-130, 2013.
34. Hagman Z, Haflidadottir BS, Ceder JA, Larne O, Bjartell A, Lilja H, Edsjo A and Ceder Y: miR-205 negatively regulates the androgen receptor and is associated with adverse outcome of prostate cancer patients. Br J Cancer 108(8) : 1668-1676, 2013.
35. Pourmand G, Ziaee AA, Abedi AR, Mehrsai A, Alavi HA, Ahmadi A and Saadati HR: Role of PTEN gene in progression of prostate cancer. Urology J 4: 95-100, 2007.
36. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, Arora VK, Kaushik P, Cerami E, Reva B, Antipin Y, Mitsiades N, Landers T, Dolgalev I, Major JE, Wilson M, Socci ND, Lash AE, Heguy A, Eastham JA, Scher HI, Reuter VE, Scardino PT, Sander C, Sawyers CL and Gerald WL: Integrative genomic profiling of human prostate cancer. Cancer Cell 18: 11-22, 2010.
37. Carver BS, Chapinski C, Wongvipat J, Hieronymus H, Chen Y, Chandarlapaty S, Arora VK, Le C, Koutcher J, Scher H, Scardino PT, Rosen N and Sawyers CL: Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTENdeficient prostate cancer. Cancer Cell 19(5) : 575-586, 2011.
38. Thomas C, Lamoureux F, Crafter C, Davies BR, Beraldi E, Fazli L, Kim S, Thaper D, Gleave ME and Zoubeidi A: Synergistic targeting of PI3K/AKT pathway and androgen receptor axis significantly delays castration-resistant prostate cancer progression in vivo. Mol Cancer Ther 12 : 2342-2355, 2013.
39. Aschelter AM, Giacinti S, Caporello P and Marchetti P: Genomic and epigenomic alterations in prostate cancer. Front Endocrinol 3 : 128, 2012.
40. Ferraldeschi R, Welti J, Luo J, Attard G and De Bono JS: Targeting the androgen receptor pathway in castration-resistant prostate cancer: progresses and prospects. Oncogene 19: 1-13, 2014.